|
|
Phibro Animal Health Corporation (PAHC) |
|
|
|
| |
PAHC's Net Income Growth by Quarter and Year
Phibro Animal Health's Net Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| PAHC Net Income (in millions $) |
FY 2024 |
FY 2023 |
FY 2022 |
FY 2021 |
| IV Quarter |
June |
0.75
|
11.50
|
7.49
|
17.12
|
| III Quarter |
March |
8.41
|
10.04
|
17.69
|
12.16
|
| II Quarter |
December |
1.27
|
7.21
|
17.47
|
12.80
|
| I Quarter |
September |
-8.02
|
3.86
|
6.53
|
12.30
|
| FY |
|
2.41
|
32.61
|
49.18
|
54.38
|
| PAHC Net Income fourth quarter 2024 Y/Y Growth Comment |
Phibro Animal Health Corporation reported drop in Net Income in the fourth quarter 2024 by -93.46% to $ 0.75 millions, from the same quarter in 2023.
This represents worst decline in recent Company history.
Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Net Income growth. While Phibro Animal Health Corporation' s Net Income meltdown of -93.46% ranks overall at the positon no. 1703 in the fourth quarter 2024.
|
| PAHC Net Income ( Y/Y Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
June |
-93.46 % |
53.54 % |
-56.25 % |
203.55 % |
| III Quarter |
March |
-16.24 % |
-43.24 % |
45.48 % |
-9.93 % |
| II Quarter |
December |
-82.39 % |
-58.73 % |
36.48 % |
7.65 % |
| I Quarter |
September |
- |
-40.89 % |
-46.91 % |
388.1 % |
| FY |
|
-92.6 % |
-33.69 % |
-9.56 % |
62.09 % |
PAHC Net Income (Quarter on Quarter Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
June |
-91.06 % |
14.54 % |
-57.66 % |
40.79 % |
| III Quarter |
March |
562.2 % |
39.25 % |
1.26 % |
-5 % |
| II Quarter |
December |
- |
86.79 % |
167.53 % |
4.07 % |
| I Quarter |
September |
- |
-48.46 % |
-61.86 % |
118.09 % |
| FY (Year on Year) |
|
-92.6 % |
-33.69 % |
-9.56 % |
62.09 % |
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 389.15 % |
16.14 % |
-93.46 % |
| (Sep 30 2020) |
|
(Jun 30 2024) |
|
|
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 389.15 % |
16.14 % |
-93.46 % |
| (Sep 30 2020) |
|
(Jun 30 2024) |
|
| Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024 |
Phibro Animal Health's Q/Q Net Income Growth
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 559.73 % |
35.58 % |
-91.05 % |
| (Mar 31 2024) |
|
|
| PAHC's IV. Quarter Q/Q Net Income Comment |
In the IV. Quarter 2024 Phibro Animal Health Corporation reported fall in Net Income sequentially by -91.06% to $ 0.75 millions, from $ 8.41 millions declared in the previous reporting period.
Those seasonal factors that commonly elevate IV. Quarter 2024 results, were not able to rescue the IV. Quarter for the Phibro Animal Health Corporation, Ana Figueiredo, market contributor wrote.
Within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Net Income quarter on quarter growth. While Phibro Animal Health's Net Income growth quarter on quarter, overall rank is 1703. |
|
|
|
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 559.73 % |
35.58 % |
-91.05 % |
| (Mar 31 2024) |
|
|
| PAHC's IV. Quarter Q/Q Net Income Comment |
In the IV. Quarter 2024 Phibro Animal Health Corporation realized fall in Net Income from the previous quarter by -91.06% to $ 0.75 millions, from $ 8.41 millions achived in the previous reporting period.
Even seasonal influence that normally fuel IV. Quarter 2024 performance, could not salvage the IV. Quarter for the Phibro Animal Health Corporation, Ana Figueiredo, market contributor wrote.
Within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Net Income quarter on quarter growth. While Phibro Animal Health's Net Income growth quarter on quarter, overall rank is 1703. |
|
Phibro Animal Health's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending
(Jun 30 2024) |
12 Months Ending
(Mar 31 2024) |
12 Months Ending
(Dec 31 2023) |
12 Months Ending
(Sep 30 2023) |
12 Months Ending
(Jun 30 2023) |
| Cumulative Net Income 12 Months Ending |
$ 2.42 |
$ 13.16 |
$ 14.80 |
$ 20.74 |
$ 32.61 |
| Y / Y Net Income Growth (TTM) |
-92.59 % |
-53.97 % |
-59.17 % |
-55.41 % |
-33.69 % |
| Year on Year Net Income Growth Overall
Ranking |
# 1625 |
# 1549 |
# 1655 |
# 1806 |
# 1672 |
| Seqeuential Net Income Change (TTM) |
-81.64 % |
-11.06 % |
-28.63 % |
-36.41 % |
14.03 % |
| Seq. Net Income Growth (TTM) Overall
Ranking |
# 1625 |
# 1549 |
# 1655 |
# 1806 |
# 1672 |
| Cumulative Net Income growth
Comment |
Phibro Animal Health's cumulative 12 months Net Income continue to drop, but on the faster rate at -92.59% year on year, at Jun 30 2024 compare to the -53.97% decrease at Mar 31 2024. If the Phibro Animal Health's fiscal year would end at Jun 30 2024, annual Net Income would be $2 millions.
In the Healthcare sector 83 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 1549 to 1625. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
68.22 % |
-8.76 % |
-92.59 % |
| (March 31, 2016) |
|
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
68.22 % |
-8.76 % |
-92.59 % |
| (March 31, 2016) |
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 11 |
| Sector |
# 53 |
| S&P 500 |
# 594 |
|
| Cumulative Net Income growth
Comment |
Phibro Animal Health's cumulative 12 months Net Income continue to drop, but on the faster rate at -92.59% year on year, at Jun 30 2024 compare to the -53.97% decrease at Mar 31 2024. If the Phibro Animal Health's fiscal year would end at Jun 30 2024, annual Net Income would be $2 millions.
In the Healthcare sector 83 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 1549 to 1625. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
68.22 % |
-8.76 % |
-92.59 % |
| (March 31, 2016) |
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
68.22 % |
-8.76 % |
-92.59 % |
| (March 31, 2016) |
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 11 |
| Sector |
# 53 |
| S&P 500 |
# 594 |
|
